Nobel Prize In Physiology Or Medicine 2 Americans 1 Japanese Awarded For Study On Immune System

Scientists won the Nobel Prize
12 followers
5 Video Views·May 16, 2026
AI Generated·May contain errors
The Nobel Assembly at Karolinska Institute has today decided to award the 2025 Nobel Prize in
Physiology or Medicine jointly to Mary Branko, Fred Ramsdell and Shimon Sakaguchi for their
discoveries concerning peripheral immune tolerance. Here are the three laureates.
Mary Branko was born in 1961 and received a PhD from Princeton University in the United States.
The work for which she's awarded was performed at a biotech company, Celtic Chiroscience in Bothell,
Washington. She's currently a senior program manager at the Institute for Systems Biology
in Seattle. Fred Ramsdell was born in 1960 and received a PhD in 1987 at the University of
California in Los Angeles. The work for which he's awarded was performed at the same biotech
company, Celtic Chiroscience. He's currently a scientific advisor at the company he himself
founded, Sonoma Biotherapeutics in San Francisco and in Seattle.
Shimon Sakaguchi was born in 1951, earned an MD in 1976 and a PhD degree in 1983 from Kyoto
University in Japan. The work for which he is awarded was initiated at Aichi Cancer
Center Research Institute in Nagoya. He's currently a distinguished professor at the
Immunology Frontier Research Center at Osaka University. I now turn to Professor Marie
Varen-Herlenius, member of the Nobel Committee, who will now describe this year's Nobel Prize
discoveries. Please, Marie. This year's Nobel Prize in Physiology or Medicine relates to how
we keep our immune system under control so we can fight all imaginable microbes and still avoid
autoimmune disease. Let me explain. We are constantly exposed to a myriad of microbes
and our immune system has developed to protect us from them. To detect all different varieties
of microbes, existing ones and ones that may come, specialized cells in our immune system,
the T cells, have receptors. We can form billions and billions of these receptors,
all with different shapes that bind to different proteins. The T cells help us fight infection
and without them we cannot live long. Among all this diversity, some T cells receptors will
unavoidably recognize proteins and structures in our own bodies, so-called self-reactivity.
These self-reactive T cells may become harmful and cause autoimmune diseases such as type 1
diabetes, multiple sclerosis and rheumatoid arthritis. So how does our body solve this
problem? From early life, our T cells are generated in the bone marrow and then travel to the thymus
where they go through a test. In this test, harmful self-reactive T cells are eliminated
in a process called central tolerance. For a long time, this was believed to be the only way
self-tolerance is obtained. However, some self-reactive cells escape out into our circulation
and are potentially dangerous. This year's Nobel Prize in Physiology or Medicine
concerns the discovery of how those potentially harmful T cells are kept in check.
The discovery started with Shimon Sakaguchi's interest in the phenomenon that removing the
thymus from mice three days after birth led to an overreactive immune system which caused
autoimmune diseases. However, if T cells from healthy mice were injected, the development
of autoimmune disease was prevented. Sakaguchi realized that among these injected cells there
must be some cells that protect against the overreactive immune system and autoimmune diseases.
He started a long search for these cells. Years later, he discovered that if the T cells to be
transferred were depleted of cells with the cell surface protein CD25, this pool of cells would no
longer protect against autoimmune diseases. But if the T cells with CD25 were also injected,
the mice were protected. Sakaguchi called these CD25 positive cells regulatory T cells.
Many researchers were, however, skeptical about the existence of regulatory T cells.
The critical missing piece would come from Mary Branco and Fred Ramsdell.
They studied a mouse strain called scurvy because of its scaly skin. The scaly skin was part of the
severe autoimmune disease the mice developed. Branco and Ramsdell wanted to find the mutation
causing the disease. Other researchers had shown that the scurvy mutation was somewhere in the
middle of the X chromosome. Today it's possible to map a mouse genome, the whole genome in a few
days, but at the time it was an incredible challenge and like looking for a needle in a
haystack. Branco and Ramsdell still took on the enormous work of mapping the middle part of the
X chromosome in detail and eventually established that the section of interest contained 20
potential genes. They then examined gene after gene. It was only with the 20th and last examined
genes that they found the mutation. The faulted gene was previously unknown but had many similarities
with a group of genes called forkhead box or fox genes and they named the new gene fox p3.
Branco and Ramsdell suspected that the rare autoimmune disease IPEX, which is also linked
to the X chromosome, could be the human variant of the scurvy mouse disease. To understand if that
was the case they analyzed samples from children with IPEX and found mutations in the fox p3 gene.
These findings connected the fox p3 gene also to human autoimmune disease. These two key
discoveries, Sakaguchi's identification of cells that regulate immune responses and Branco's and
Ramsdell's identification of the fox p3 gene as important for keeping the immune system in control
indicated that the fox p3 gene could be important for regulatory T cells.
Shimon Sakaguchi was first to show that fox p3 is actually essential for the development
of the regulatory T cells, so-called Tregs, and therefore critical in the peripheral immune
tolerance. This was soon followed by reports from other scientists and unleashed a whole new field
in immunology. Subsequent studies show that when autoreactive T cells get activated,
the regulatory T cells act to control them, both through cell-cell contacts and by soluble
molecules. In this way, immune tolerance can be maintained without deleting too many T cells,
which could be needed for our protection against current or future microbes. The discoveries have
spurred development of several potential new treatments. Clinical trials are ongoing to
increase the number of regulatory T cells for suppressing unwanted immune reactions in autoimmune
disease or following organ transplantation. This is done either by injecting growth factors that
stimulate regulatory T cells or by multiplying regulatory T cells in laboratories, which can
then be given to patients. The opposite approach is used in trials for cancer. Cancer cells can
make use of our regulatory T cells to avoid immune reactions that could destroy the cancer cells.
For cancer treatments, the focus is therefore on down-regulating or destroying the regulatory
T cells so that our immune system can act against the malignant cells. To summarize,
Mary Branco, Fred Ransdell, and Shimon Sakaguchi have provided fundamental knowledge of how the
immune system is regulated and are therefore awarded this year's Nobel Prize in Physiology
or Medicine for their discoveries concerning peripheral immune tolerance.
